Chiesi Group is buying biopharmaceutical group Zymenex Holding A/S for an undisclosed amount.

Hilleroed, Denmark-based Zymenex is focused on research and development of treatments for rare genetic diseases.  The company makes Lamazym, used to treat patients with alpha-Mannosidosis, a disorder that causes problems in many organs.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.